Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge.
about
Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspectsThe M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner.Pathogenesis and prevention of placental and transplacental porcine reproductive and respiratory syndrome virus infection.Comparative measurement of cell-mediated immune responses of swine to the M and N proteins of porcine reproductive and respiratory syndrome virus.Attenuation and immunogenicity of a live high pathogenic PRRSV vaccine candidate with a 32-amino acid deletion in the nsp2 proteinDetection of total and PRRSV-specific antibodies in oral fluids collected with different rope types from PRRSV-vaccinated and experimentally infected pigsRecombinant Kluyveromyces lactis expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP5 elicits mucosal and cell-mediated immune responses in mice.Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virusProtective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5.A new modified live porcine reproductive and respiratory syndrome vaccine improves growth performance in pigs under field conditions.Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.Risk factors for porcine reproductive and respiratory syndrome virus infection and resulting challenges for effective disease surveillance.Boosting in planta production of antigens derived from the porcine reproductive and respiratory syndrome virus (PRRSV) and subsequent evaluation of their immunogenicity.The assessment of efficacy of porcine reproductive respiratory syndrome virus inactivated vaccine based on the viral quantity and inactivation methods.Molecular characterization of transcriptome-wide interactions between highly pathogenic porcine reproductive and respiratory syndrome virus and porcine alveolar macrophages in vivo.Comparative analysis of cytokine transcript profiles within mediastinal lymph node compartments of pigs after infection with porcine reproductive and respiratory syndrome genotype 1 strains differing in pathogenicityDifferent clinical, virological, serological and tissue tropism outcomes of two new and one old Belgian type 1 subtype 1 porcine reproductive and respiratory virus (PRRSV) isolates.Metabolic variations, antioxidant potential, and antiviral activity of different extracts of Eugenia singampattiana (an endangered medicinal plant used by Kani tribals, Tamil Nadu, India) leaf.Assessment of the safety and efficacy of an attenuated live vaccine based on highly pathogenic porcine reproductive and respiratory syndrome virus.A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB.The presence of alpha interferon at the time of infection alters the innate and adaptive immune responses to porcine reproductive and respiratory syndrome virusThe Non-structural Protein 5 and Matrix Protein Are Antigenic Targets of T Cell Immunity to Genotype 1 Porcine Reproductive and Respiratory Syndrome Viruses.Deciphering transcriptome profiles of peripheral blood mononuclear cells in response to PRRSV vaccination in pigs.Recognition of Highly Diverse Type-1 and -2 Porcine Reproductive and Respiratory Syndrome Viruses (PRRSVs) by T-Lymphocytes Induced in Pigs after Experimental Infection with a Type-2 PRRSV Strain.Ability of ELISAs to detect antibodies against porcine respiratory and reproductive syndrome virus in serum of pigs after inactivated vaccination and subsequent challengeOverexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.Prediction and in vitro verification of potential CTL epitopes conserved among PRRSV-2 strains.Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditionsComparative effects of vaccination against porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) in a PCV2-PRRSV challenge modelComparative analysis of routes of immunization of a live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in a heterologous virus challenge study.Comparison of 2 commercial single-dose Mycoplasma hyopneumoniae vaccines and porcine reproductive and respiratory syndrome virus (PRRSV) vaccines on pigs dually infected with M. hyopneumoniae and PRRSVSafety and early onset of immunity with a novel European porcine reproductive and respiratory syndrome virus vaccine in young piglets.The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.Evaluation of the new commercial recombinant chimeric subunit vaccine PRRSFREE in challenge with heterologous types 1 and 2 porcine reproductive and respiratory syndrome virus.Vaccination of sows against type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) before artificial insemination protects against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge in late gestationAssessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus.Porcine reproductive and respiratory syndrome virus vaccines: current status and strategies to a universal vaccine.Overview: Replication of porcine reproductive and respiratory syndrome virus.
P2860
Q26825847-A300E46A-34F5-4020-988D-C060F2B5E4A6Q33525023-8117A21B-5F5D-43BE-A008-9E45EF25993FQ33613149-B8FBDEE1-70BF-424E-8897-73524380220CQ33768736-207DD70D-BD52-4170-9B5D-17E0FB085025Q33804235-1F9D4293-4F49-4A7D-9B04-64CD9DE88B8CQ33813131-0B1F3F31-620B-4545-9C12-1F0D9ED9BBD8Q33865394-BD24FAE4-2598-4C33-978D-1C597C4D062CQ34019891-C3C045F7-F169-46FE-9E29-C0272C379366Q34121223-ACC47BA2-4F53-4D22-ADEF-4AB441CF6635Q34121241-430BD5FB-9251-49B1-8D97-17F795284E2CQ34260827-8ECE9294-AF0A-4A4C-9972-CC3E8BC7D586Q34432119-6DFA855B-F6B5-46E1-BEFF-C08BA15CBA1AQ34433140-238FFD3D-6DE2-4DB5-B933-3D06180FA833Q35116494-FAA75D81-8BE8-45BB-832E-B758DF6D1035Q35122248-1F8BEC78-2CB3-4E08-8EC9-FD58E8DD9584Q35168206-7BAD189C-C70E-4100-9BA7-DF124B32FBFCQ35191056-03C297B2-925D-456F-B5A6-CE903B64F2F6Q35200948-25BC821B-F620-4A36-BAD5-0F3502FE8F16Q35226983-CFBBB6D0-6C43-4AC0-812D-67BA063EB719Q35548036-916F641E-20E7-40C8-ADBF-C1D9758A5715Q35639638-02445ED8-8B99-496B-BCDB-8895792D1F4CQ35867206-4DFBB3E8-7B8B-401D-9C86-3B82BCCB5EBCQ35933545-59B40A33-9002-4305-908A-A4FED70B9238Q36104682-BF3ACEE7-82CC-4E16-9A55-8C4490B4BB7AQ36178539-BFE04E59-3E6B-48DB-888F-766135A3EE89Q36200289-7560FDFE-0138-4777-83D2-8EBC06FF097BQ36239538-818BEE09-F90E-4249-81AC-A0EA539CAFCEQ36281179-99D04ABD-5F05-40E3-B96B-12F6463C96E2Q36394575-3A5DB5DF-0D8D-4C1D-AC9E-584954C7DDDAQ36547978-D4354F75-8D32-4F06-8AC9-7BA4CB6A9CC4Q36668529-503ABFBD-11E2-4EE6-ADD9-3E88ABEBB526Q36700988-21682206-DD27-4F4E-AEB6-653DF0B961F0Q36811008-B290BA56-5A3C-4F3B-A043-E2038A60F549Q36811013-CC535597-D1EC-42CE-82B8-9D0EF6D6A83DQ36811916-53C5ABDC-87AA-4980-B908-D3818039D98EQ37572027-A7568F00-AD00-4966-95F4-264B63F0E015Q37582096-D8A40490-1710-4F2D-8ACA-4D3D671AF962Q37623519-8F095628-6E89-47EB-91A8-53EB398738B5Q38076180-155E2A20-12DC-4CB8-97AA-456A9C84FDFCQ38175363-F1749B29-4C52-4ABE-8908-27075F027BAB
P2860
Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Assessment of the efficacy of ...... of protection upon challenge.
@en
Assessment of the efficacy of ...... of protection upon challenge.
@nl
type
label
Assessment of the efficacy of ...... of protection upon challenge.
@en
Assessment of the efficacy of ...... of protection upon challenge.
@nl
prefLabel
Assessment of the efficacy of ...... of protection upon challenge.
@en
Assessment of the efficacy of ...... of protection upon challenge.
@nl
P2093
P1476
Assessment of the efficacy of ...... of protection upon challenge.
@en
P2093
Alan Doster
Esther Alvarez Garcia
Federico A Zuckermann
Fernando Osorio
Ivan Diaz Luque
Jane Christopher-Hennings
Monica Brito
P356
10.1016/J.VETMIC.2007.02.009
P577
2007-02-16T00:00:00Z